Pegfilgrastim

Summary

Pegfilgrastim (CHEMBL1201568) is an approved protein (ATC L03AA13) targeting CSF3R; indicated across 70 conditions including neoplasm and neutropenia.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: L03AA13
• Targets: 1 (CSF3R)
• Indications: 70 conditions
• Clinical trials: 257

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201568
Name	Pegfilgrastim
Type	Protein
Max phase	4
ATC	L03AA13

Also known as: B-12019, B12019, Cegfila, Chs-1701, Fulphila, Fylnetra, Grasustek, Hsp-130, LA EP 2006, LA EP-2006, La-ep2006, Lupifil-p

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
CSF3R	Granulocyte colony-stimulating factor receptor	Agonist		0.9%	Q99062

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): CSF3R.

Top Reactome pathways

4 total, by targets touching each:

Pathway	Targets	Genes
Other interleukin signaling	1	CSF3R
Transcriptional regulation of granulopoiesis	1	CSF3R
Signaling by CSF3 (G-CSF)	1	CSF3R
Inactivation of CSF3 (G-CSF) signaling	1	CSF3R

Dominant GO biological processes

GO term	Targets
defense response	1
cell adhesion	1
signal transduction	1
positive regulation of cell population proliferation	1
cytokine-mediated signaling pathway	1
neutrophil chemotaxis	1
regulation of myeloid cell differentiation	1
amelogenesis	1

Indications & clinical

Indications

2 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
neoplasm	4	MONDO:0005070	EFO:0000616
neutropenia	4	MONDO:0001475	MONDO:0001475

58 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
plasma cell myeloma	3	MONDO:0009693	EFO:0001378
breast carcinoma	3	MONDO:0004989	EFO:0000305
lymphoma	3	MONDO:0005062	EFO:0000574
non-small cell lung carcinoma	3	MONDO:0005233	EFO:0003060
Hodgkins lymphoma	3	MONDO:0004952	EFO:0000183
diffuse large B-cell lymphoma	3	MONDO:0018905	EFO:0000403
germ cell tumor	3	MONDO:0005040	EFO:0000514
sarcoma	3	MONDO:0005089	EFO:0000691
triple-negative breast carcinoma	3	MONDO:0005494	EFO:0005537
breast neoplasm	3	MONDO:0021100	EFO:0003869
lung neoplasm	3	MONDO:0021117	MONDO:0008903
uterine corpus cancer	3	MONDO:0006003	EFO:0007532
adrenal cortex carcinoma	3	MONDO:0006639	EFO:1000796
tumor of uterus	3	MONDO:0021353	EFO:0003859
leukemia	2	MONDO:0005059	EFO:0000565
non-Hodgkin lymphoma	2	MONDO:0018908	EFO:0005952
lymphoid neoplasm	2	MONDO:0005157	EFO:0001642
head and neck squamous cell carcinoma	2	MONDO:0010150	EFO:0000181
acute lymphoblastic leukemia	2	MONDO:0004967	EFO:0000220
acute myeloid leukemia	2	MONDO:0018874	EFO:0000222
renal cell carcinoma	2	MONDO:0005086	EFO:0000681
small cell lung carcinoma	2	MONDO:0008433	EFO:0000702
melanoma	2	MONDO:0005105	EFO:0000756
head and neck cancer	2	MONDO:0005627	EFO:0006859
male breast carcinoma	2	MONDO:0005628	EFO:0006861
mantle cell lymphoma	2	MONDO:0018876	EFO:1001469
myelodysplastic syndrome	2	MONDO:0018881	EFO:0000198
medulloblastoma	2	MONDO:0007959	EFO:0002939
urothelial carcinoma	2	MONDO:0040679	EFO:0008528
aplastic anemia	2	MONDO:0015909	HP:0001915
peripheral T-cell lymphoma, not otherwise specified	2	MONDO:0004964	EFO:0000211
lung adenocarcinoma	2	MONDO:0005061	EFO:0000571
rectal cancer	2	MONDO:0006519	EFO:1000657
gastric neoplasm	2	MONDO:0021085	MONDO:0001056
peritoneal neoplasm	2	MONDO:0006901	MONDO:0002087
fallopian tube neoplasm	2	MONDO:0021092	MONDO:0002158
myeloid leukemia	2	MONDO:0004643	MONDO:0004643
ovarian cancer	2	MONDO:0008170	MONDO:0008170
colonic neoplasm	2	MONDO:0005401	MONDO:0021063
type 1 diabetes mellitus	2	MONDO:0005147	MONDO:0005147
Wilms tumor	2	MONDO:0006058	MONDO:0006058
retinoblastoma	2	MONDO:0008380	MONDO:0008380
metastatic prostate carcinoma	2	MONDO:0004956	EFO:0000196
exocrine pancreatic carcinoma	2	MONDO:0005192	EFO:0002618
pancreatic endocrine carcinoma	2	MONDO:0005893	EFO:0007416
plasma cell neoplasm	2	MONDO:0004959	EFO:0000200
lung large cell carcinoma	2	MONDO:0003050	EFO:0003050
testicular cancer	2	MONDO:0005447	EFO:0004281
colorectal neoplasm	2	MONDO:0005335	MONDO:0005575
nasopharyngeal carcinoma	2	MONDO:0015459	MONDO:0015459
carcinoid tumor	2	MONDO:0005369	MONDO:0024503
neuroblastoma	1	MONDO:0005072	EFO:0000621
osteosarcoma	1	MONDO:0009807	EFO:0000637
primary cutaneous T-cell non-Hodgkin lymphoma	1	MONDO:0000607	EFO:0002913
brain cancer	1	MONDO:0001657	MONDO:0001657
follicular lymphoma	1	MONDO:0018906	MONDO:0018906
coronary artery disorder	1	MONDO:0005010	EFO:0001645
central nervous system cancer	1	MONDO:0002714	EFO:0000326

10 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 257.

Phase distribution

Phase	Trials
PHASE2	123
PHASE1	47
PHASE3	41
PHASE1/PHASE2	23
Not specified	13
PHASE4	5
PHASE2/PHASE3	4
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00030758	PHASE4	UNKNOWN	Filgrastim or Pegfilgrastim in Preventing Neutropenia in Women Receiving Chemotherapy Following Surgery for Breast Cancer
NCT00277160	PHASE4	COMPLETED	A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer
NCT02782845	PHASE4	COMPLETED	An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin’s Lymphoma (NHL)
NCT03511378	PHASE4	COMPLETED	Immunogenicity Assessment of Peg-filgrastim vs. Neulasta® as Adjunct to Chemotherapy in Patients With Breast Cancer
NCT04781959	PHASE4	COMPLETED	A Randomized, Multicenter Pragmatic Trial Comparing Bone Pain From a Single Dose of Pegfilgrastim to 5 Doses of Daily Filgrastim in Breast Cancer Patients Receiving Neoadjuvant/Adjuvant Chemotherapy
NCT00070564	PHASE3	ACTIVE_NOT_RECRUITING	S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer
NCT00433420	PHASE3	ACTIVE_NOT_RECRUITING	Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer
NCT03907488	PHASE3	ACTIVE_NOT_RECRUITING	Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
NCT04628767	PHASE2/PHASE3	RECRUITING	Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
NCT04759586	PHASE3	ACTIVE_NOT_RECRUITING	Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
NCT06188676	PHASE3	RECRUITING	Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL
NCT06220032	PHASE3	RECRUITING	Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma
NCT06520176	PHASE3	RECRUITING	Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients
NCT00006011	PHASE3	COMPLETED	Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer
NCT00035594	PHASE3	COMPLETED	Pegfilgrastim as Support to Advanced Breast Cancer Patients Receiving Chemotherapy
NCT00049595	PHASE3	COMPLETED	Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin’s Lymphoma
NCT00061984	PHASE3	COMPLETED	Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma
NCT00063999	PHASE3	COMPLETED	Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
NCT00113386	PHASE3	TERMINATED	Cisplatin and Docetaxel With or Without Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Newly Diagnosed Stage III Non-Small Cell Lung Cancer
NCT00117910	PHASE3	COMPLETED	Treatment for Elderly Patients With High Risk Breast Cancer
NCT00118209	PHASE3	COMPLETED	Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin’s Lymphoma
NCT00151242	PHASE2/PHASE3	COMPLETED	Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT00301925	PHASE3	UNKNOWN	Combination Chemotherapy in Treating Patients With Early Stage Breast Cancer That Has Been Removed By Surgery
NCT00304070	PHASE3	COMPLETED	Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor
NCT00499018	PHASE3	UNKNOWN	Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma
NCT00516425	PHASE3	UNKNOWN	Doxorubicin or Epirubicin and Cyclophosphamide in Treating Older Women With Invasive Breast Cancer
NCT00536081	PHASE3	COMPLETED	Various G-CSF Regimens to Prevent Infection During Chemotherapy
NCT00574080	PHASE3	TERMINATED	UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide
NCT00678327	PHASE3	COMPLETED	Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma
NCT00837265	PHASE2/PHASE3	COMPLETED	Balugrastim (Neugranin) in Breast Cancer Participants Receiving Doxorubicin/Docetaxel
NCT00887536	PHASE3	COMPLETED	A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
NCT00911170	PHASE3	COMPLETED	PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
NCT01012297	PHASE3	TERMINATED	Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma
NCT01126190	PHASE3	COMPLETED	Neugranin in Breast Cancer Participants Receiving Doxorubicin/Docetaxel
NCT01516736	PHASE3	COMPLETED	Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
NCT01533207	PHASE3	TERMINATED	Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery
NCT01735175	PHASE3	COMPLETED	Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Neulasta®
NCT02044276	PHASE3	COMPLETED	A comparatiVe Study on Efficacy and Safety of Lipegfilgrastim in Comparison to Pegfilgrastim in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced Neutropenia
NCT02238873	PHASE3	UNKNOWN	Pegfilgrastim on Day +3 Compared to Day +1 After Salvage Chemotherapy for Patients With Refractory or Relapsed Aggressive Lymphoma
NCT02467868	PHASE3	COMPLETED	Efficacy and Safety Study With MYL-1401H and Neulasta
NCT02643420	PHASE3	COMPLETED	SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE)
NCT02768714	PHASE3	WITHDRAWN	Trial to Compare the Efficacy and Safety of Pegfilgrastim Biosimilar in Subjects With High Risk Stage Breast Cancer Receiving Chemotherapy
NCT02953340	PHASE3	COMPLETED	SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide
NCT03102606	PHASE3	COMPLETED	Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3
NCT03197935	PHASE3	COMPLETED	A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer
NCT03252431	PHASE3	COMPLETED	Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
NCT03294577	PHASE3	UNKNOWN	Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia
NCT03404752	PHASE3	UNKNOWN	Pegfilgrastim-gema Compared to Pegfilgrastim-roche for Prevention of Induced Neutropenia in Breast Cancer Patients.
NCT05283616	PHASE3	COMPLETED	Reduced Dose of Pegfilgrastim as Support for Chemotherapy for Breast Cancer
NCT05870748	PHASE2/PHASE3	TERMINATED	REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator’s Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
NCT00334815	PHASE2	ACTIVE_NOT_RECRUITING	Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
NCT01624805	PHASE2	RECRUITING	Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
NCT01783535	PHASE2	ACTIVE_NOT_RECRUITING	Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma
NCT03136146	PHASE2	RECRUITING	Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
NCT03147612	PHASE2	ACTIVE_NOT_RECRUITING	Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia
NCT03214562	PHASE1/PHASE2	RECRUITING	Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
NCT03571633	PHASE2	ACTIVE_NOT_RECRUITING	Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer
NCT03609216	PHASE2	ACTIVE_NOT_RECRUITING	Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations
NCT03943901	PHASE2	ACTIVE_NOT_RECRUITING	Split-Dose R-CHOP for Older Adults With DLBCL
NCT04684368	PHASE2	RECRUITING	A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
NCT05011188	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer
NCT05535166	PHASE2	RECRUITING	Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
NCT05645718	PHASE2	RECRUITING	Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
NCT06023641	PHASE2	RECRUITING	Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
NCT06528691	PHASE2	RECRUITING	Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors
NCT06594939	PHASE2	NOT_YET_RECRUITING	Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma
NCT06690775	PHASE2	RECRUITING	CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
NCT06709495	PHASE1/PHASE2	RECRUITING	Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
NCT06738368	PHASE2	RECRUITING	Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia
NCT07021989	PHASE2	NOT_YET_RECRUITING	ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma
NCT07059611	PHASE2	NOT_YET_RECRUITING	Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma
NCT07064018	PHASE1/PHASE2	RECRUITING	Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies
NCT07224100	PHASE2	RECRUITING	Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma
NCT00003955	PHASE2	COMPLETED	Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Metastatic Rhabdomyosarcoma or Sarcoma
NCT00004192	PHASE2	COMPLETED	Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin’s Lymphoma
NCT00031629	PHASE2	COMPLETED	Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus
NCT00035620	PHASE2	COMPLETED	Pegfilgrastim as Support to Pediatric Sarcoma Patients Receiving Chemotherapy
NCT00063934	PHASE1/PHASE2	TERMINATED	Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer
NCT00066092	PHASE2	COMPLETED	Pegfilgrastim PBPC Mobilization Study
NCT00066443	PHASE1/PHASE2	COMPLETED	Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer
NCT00067639	PHASE2	COMPLETED	Pegfilgrastim (Neulasta) for Stem Cell Mobilization in Patients With Multiple Myeloma
NCT00068393	PHASE2	COMPLETED	Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma
NCT00069953	PHASE2	COMPLETED	Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
NCT00073983	PHASE2	COMPLETED	Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing’s Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma
NCT00074165	PHASE2	TERMINATED	Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen
NCT00074178	PHASE2	COMPLETED	Methotrexate, Cyclophosphamide, and Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Dexamethasone and Cytarabine in Treating Patients With Primary CNS Lymphoma
NCT00077103	PHASE1/PHASE2	TERMINATED	Induction Chemotherapy Using Doxorubicin and Cisplatin Followed by Combretastatin A4 Phosphate and Radiation Therapy in Treating Patients With Newly Diagnosed Regionally Advanced Anaplastic Thyroid Cancer
NCT00077311	PHASE2	COMPLETED	Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00080626	PHASE2	TERMINATED	Neoadjuvant Docetaxel in Treating Women With Newly Diagnosed Breast Cancer
NCT00086944	PHASE1/PHASE2	COMPLETED	Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin’s Lymphoma
NCT00094809	PHASE2	COMPLETED	Chemotherapy Administered Every 2 Weeks With or Without Pegfilgrastim in Subjects With Advanced or Metastatic Colon Cancer
NCT00101010	PHASE2	COMPLETED	Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma
NCT00101127	PHASE2	COMPLETED	Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma
NCT00107510	PHASE2	COMPLETED	Docetaxel, Carboplatin, and Pegfilgrastim in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer
NCT00114764	PHASE2	COMPLETED	Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML)
NCT00115193	PHASE2	COMPLETED	Pegfilgrastim Administered on the Same Day as Chemotherapy in Non-Hodgkin’s Lymphoma
NCT00115414	PHASE2	COMPLETED	Same Day Dosing of Pegfilgrastim in Breast Cancer Patients Undergoing Chemotherapy (TAC)
NCT00117442	PHASE2	COMPLETED	A Study of Carboplatin/Paclitaxel With Pegfilgrastim Supported by Haematopoietic Progenitor Cell Re-Infusion in Whole Blood
NCT00117455	PHASE2	COMPLETED	A Study of Peripheral Blood Progenitor Cell (PBPC) Mobilisation by Chemotherapy With Pegfilgrastim or Filgrastim in Subjects With Non-Hodgkin’s Lymphoma
NCT00117897	PHASE2	COMPLETED	Treatment for Subjects With Non-Hodgkin’s Lymphoma

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).